ArticleFrontiers in endocrinology2025
Post-thyroidectomy ultrasonography versus thyroglobulin as a surveillance tool for locoregional recurrence in patients with differentiated thyroid carcinoma: A single centre 10-year study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated thyroid cancer (DTC; including papillary and follicular thyroid cancers) has favourable survival outcomes, with related mortality below 10%. However, 20-30% of patients experience recurrence. Surveillance primarily relies on neck ultrasonography (US) and serum thyroglobulin (Tg) assessment. Purpose: This study evaluated the diagnostic performance of neck US in detecting locoregional recurrence following total thyroidectomy and compared its effectiveness with serum Tg. Materials and methods: This retrospective, single-centre study analysed 941 DTC patients who underwent total thyroidectomy and neck US between 2009 and 2019. Suspicious US findings were correlated with serum Tg levels and anti-thyroglobulin antibody status. Disease persistence (<6 months)/recurrence (>6 months) was confirmed via fine-needle aspiration cytology/biopsy, iodine scintigraphy, CT, or PET-CT. Patients without US-detected lesions were assessed clinically, biochemically, and via follow-up US. Results: Neck US had a sensitivity of 98.9%, specificity of 63.1%, positive predictive value (PPV) of 50.7%, negative predictive value (NPV) of 99.3%, and an accuracy of 73.01%. Serum Tg (cutoff 1.8 ng/ml derived from receiver operating characteristic analysis) had a sensitivity of 69.2%, specificity of 91.8%, PPV of 61.4%, NPV of 94.1%, and an accuracy of 88.28%. Among 149 patients with US-detected lesions and Tg <1.8 ng/ml, 22 (14.8%) had locoregional recurrence. Five of 43 patients with Tg <0.1 ng/ml had confirmed recurrence. Among lymph nodes ≤6 mm in short-axis diameter with an indistinct fatty hilum, 69.6% were benign. Persistence was detected in 38.5% of patients within six months post-treatment, whereas most true recurrences (61.5%) manifested after six months. Conclusion: Neck US is highly sensitive but moderately specific for detecting locoregional recurrence post-thyroidectomy, complementing Tg. Study limitations include its retrospective design, single-centre setting, and lack of inter-observer variability assessment. A risk-adapted multimodal surveillance strategy with 6-monthly US for two years is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.